-
Zverev stunned by Davidovich Fokina in Shanghai semi-finals
-
Pope to return to Vatican after cancer surgery
-
France faces day of cost-of-living protests
-
Haze triggers highest-level alert in parts of Southeast Asia
-
Zelensky says Trump waiving sanctions 'rewards' Putin, warns Moscow wants 'blackout' in Ukraine
-
I'd have left Real Madrid if I were Vinicius, says Mourinho
-
Noosha Aubel: vezetői kudarc új kezdet helyett – alkalmas-e Potsdam polgármestere a tisztsége betöltésére?
-
نوشا آوبل: ناکامی در مدیریت بهجای آغازی نو؛ آیا شهردار پوتسدام از عهدهٔ مسئولیتهایش برمیآید؟
-
Нуша Аубел: управленски провал вместо ново начало — на висотата на поста си ли е кметицата на Потсдам?
-
Noosha Aubel: eșec la conducere în locul unui nou început – este primărița Potsdamului la înălțimea funcției sale?
-
Russia hails Trump waiving sanctions as 'historic'
-
Noosha Aubel: falend leiderschap in plaats van een nieuwe start – is de burgemeester van Potsdam berekend op haar taak?
-
Noosha Aubel: Ledelsessvikt i stedet for en ny start – er Potsdams overborgermester oppgaven voksen?
-
Noosha Aubel: Misslyckat ledarskap i stället för en nystart – är Potsdams överborgmästare vuxen uppgiften?
-
Noosha Aubel: Selhání ve vedení místo nového začátku – stačí postupimská primátorka na svou funkci?
-
Wallabies coach Kiss calls latest All Blacks humbling 'unacceptable'
-
Haze triggers highest-level alert in parts of Southeast Asia: monitor
-
Superstar horse Ka Ying Rising loses first race in 22 starts at The Everest
-
IMF chief flags 'optimism', 'worry' after Bangkok annual meetings
-
Rampant All Blacks crush Wallabies 43-21 to extend dominance
-
IMF chief says has 'optimism' and 'worry' after Bangkok annual meetings
-
All Blacks crush Wallabies 43-21 to extend dominance
-
Hong Kong superstar Ka Ying Rising loses first race in 22 starts at The Everest
-
'No Kings' movement seeks to boost early voting
-
Attacks on Gulf energy infrastructure 'worrying' for outlook: Pakistan finance minister
-
Trump waives new Russia sanctions as Ukraine ties slump
-
Japan says hosting record number of foreigners
-
Tiny Fiji village restores dying fishery with coral planting
-
'Two bad options': Rights groups decry IMF austerity demand
-
North Korea says tested AI-assisted torpedo system
-
Guardians-Rays MLB playoff game postponed until Saturday
-
Did Chinese cars squeal on Norway's military?
-
'We've never had this': Bear sightings spook Russia
-
Guardians-Rays MLB playoff game start delayed by rain
-
Injured Jordie Barrett out of second Bledisloe Cup Test
-
Suspected gunman in Oregon school shooting was 'withdrawn,' neighbors say
-
All contenders for UN chief receive veto: diplomat
-
As Champions Cup opens on mournful note, holders Bordeaux-Begles draw
-
UN climate panel fails to agree date for global warming update: envoy
-
Figueroa loses title at weigh-in but Kameda can win it
-
Stocks struggle to bounce back from AI angst-fueled rout
-
Deforestation in Brazil Amazon hits nearly four-decade low
-
Clashes grip Tirana as Albanian PM blames 'foreign hands'
-
US budget deficit grows to nearly $2 trillion, highest since 2021
-
End of a dynasty? Dodgers digest playoff drubbing
-
Bend grieves after mass shooting: 'Who would do this to little kids?'
-
Troyes sack sporting director Blanchard amid sexism claims
-
'Great hero' praised for saving lives in Oregon school shooting
-
Trump's new press secretary out after less than week
-
Trump's new press secretary looks close to exit after just one week
AstraZeneca withdraws Covid vaccine as demand dives
Anglo-Swedish drugmaker AstraZeneca on Wednesday said it was withdrawing Covid vaccine Vaxzevria, one of the first produced in the deadly pandemic, citing "commercial reasons" following a slump in demand.
"As multiple, variant Covid-19 vaccines have since been developed there is a surplus of available updated vaccines. This has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied," an AstraZeneca spokesperson added in a statement.
"We will now work with regulators and our partners to align on a clear path forward to conclude this chapter and significant contribution to the Covid-19 pandemic."
AstraZeneca rapidly developed the successful Covid-19 jab during the coronavirus pandemic which erupted in the first half of 2020.
Vaxzevria, developed alongside Oxford University, was at first offered at cost but Astra decided in late 2021 to sell it for profit.
But the world pivoted towards mRNA vaccines, particularly the one produced by US drugs giant Pfizer and German peer BioNTech, after rare blood-clot problems with Astra's jab increased public hesitancy about taking it.
Sales collapsed further as global Covid restrictions were fully lifted worldwide and the world emerged from the global health crisis.
The AstraZeneca spokesperson said the group had begun the process from taking it off the market in the Europe, Middle East and Africa (EMA) region.
The company will work with other regulators globally to start market authorisation withdrawals for the Vaxzevria "where no future commercial demand for the vaccine is expected".
The spokesperson said that, according to independent estimates, "over 6.5 million lives were saved in the first year of use alone" and more than three billion doses were supplied globally.
"We are incredibly proud of the role Vaxzevria played in ending the global pandemic," the spokesperson said.
"Our efforts have been recognised by governments around the world and are widely regarded as being a critical component of ending the global pandemic. "
B.Mahmoud--SF-PST